| 2025-08-04 | +37.9% | earnings | Seeking Alpha | Castle Biosciences GAAP EPS of $0.15 beats by $0.68, revenue of $86.19M beats by $14.78M |
| 2025-08-04 | +37.9% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-08-04 | +37.9% | news | simplywall.st | Shareholders in Castle Biosciences (NASDAQ:CSTL) have lost 65%, as stock drops 10% this past week - simplywall.st |
| 2023-06-05 | -35.3% | news | The Motley Fool | Why Shares of Castle Biosciences Plummeted on Monday - The Motley Fool |
| 2025-11-04 | +30.0% | earnings | Seeking Alpha | Castle Biosciences outlines $33B AdvanceAD-Tx market opportunity while raising 2025 revenue guidance |
| 2025-11-04 | +30.0% | earnings | Seeking Alpha | Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript |
| 2025-08-05 | +28.7% | earnings | Seeking Alpha | Castle Biosciences raises 2025 revenue guidance to $310M–$320M following strong Q2 execution and test volume growth |
| 2025-08-05 | +28.7% | earnings | Seeking Alpha | Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript |
| 2024-02-28 | -28.2% | legal | SEC EDGAR | CSTL 8-K: 2.02 and 7.01 (SEC Filing) |
| 2025-11-03 | +25.0% | earnings | Seeking Alpha | Castle Biosciences Non-GAAP EPS of -$0.02 beats by $0.49, revenue of $83M beats by $11.86M |
| 2025-11-03 | +25.0% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-11-03 | +25.0% | earnings | Yahoo Finance | Castle Biosciences Inc (CSTL) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance |
| 2024-03-01 | +16.7% | earnings | GuruFocus | Castle Biosciences Inc (CSTL) Stock Earnings Transcripts - GuruFocus |
| 2025-02-27 | -16.7% | earnings | Seeking Alpha | Castle Biosciences GAAP EPS of $0.32 beats by $0.27, revenue of $86.3M beats by $2.41M |
| 2025-02-27 | -16.7% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-01-13 | -16.1% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-04-04 | -16.1% | legal | SEC EDGAR | CSTL 8-K: 1.01, 3.02 (SEC Filing) |
| 2025-02-28 | -15.6% | earnings | Seeking Alpha | Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript |
| 2025-02-28 | -15.6% | earnings | Seeking Alpha | Castle Biosciences, Inc. 2024 Q4 - Results - Earnings Call Presentation |
| 2023-08-02 | +13.9% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-08-05 | +13.8% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-19 | -13.7% | earnings | Yahoo Finance | Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance |
| 2025-05-05 | -12.7% | earnings | Seeking Alpha | Castle Biosciences Non-GAAP EPS of -$0.20 misses by $0.13, revenue of $87.99M beats by $7.61M |
| 2025-05-05 | -12.7% | news | Seeking Alpha | Castle Biosciences to buy Previse |
| 2025-05-05 | -12.7% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-27 | -11.8% | earnings | Seeking Alpha | Castle Biosciences, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-02-27 | -11.8% | earnings | Seeking Alpha | Castle Biosciences outlines 2026 revenue target of $340M-$350M as AdvanceAD-Tx launch supports growth strategy |
| 2026-02-27 | -11.8% | earnings | Seeking Alpha | Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript |
| 2023-11-02 | +11.7% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-07-11 | -11.1% | earnings | Seeking Alpha | Castle Biosciences: Reimbursement Reversal Win Masks Profitability Problem (NASDAQ:CSTL) - Seeking Alpha |
| 2022-04-07 | -9.8% | legal | SEC EDGAR | CSTL 8-K: 1.01 (SEC Filing) |
| 2022-10-30 | +9.6% | analyst | eToro | CSTL Stock Price | Analyst Target 45.50 & Consensus - eToro |
| 2026-04-08 | -8.8% | earnings | Stock Titan | Strong 2025 revenue and governance focus in Castle Biosciences (CSTL) proxy - Stock Titan |
| 2026-04-08 | -8.8% | executive | Stock Titan | Castle Biosciences (CSTL) CEO pre-planned sale of 9,836 shares after option exercise - Stock Titan |
| 2026-04-08 | -8.8% | legal | Stock Titan | [ARS] CASTLE BIOSCIENCES INC SEC Filing - Stock Titan |
| 2026-04-08 | -8.8% | executive | Investing.com | Castle Biosciences CEO sells shares worth $246,195 - Investing.com |
| 2026-04-08 | -8.8% | earnings | MarketBeat | Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,214 Shares of Stock - MarketBeat |
| 2025-05-06 | -8.6% | earnings | Seeking Alpha | Castle Biosciences projects $287-$297M revenue for 2025 amid strategic acquisitions and growth initiatives |
| 2025-05-06 | -8.6% | earnings | Seeking Alpha | Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript |
| 2024-05-02 | +8.3% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-05-02 | +8.3% | earnings | InvestorPlace | CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024 - InvestorPlace |
| 2022-01-05 | -7.9% | legal | SEC EDGAR | CSTL 8-K: 5.02 and (SEC Filing) |
| 2023-01-09 | +7.8% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-05-10 | -7.7% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-12-28 | +7.1% | legal | SEC EDGAR | CSTL 8-K: 5.02 (SEC Filing) |
| 2024-11-04 | -7.0% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-11-08 | -7.0% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-03-17 | +7.0% | legal | SEC EDGAR | CSTL 8-K: 1.01 and (SEC Filing) |
| 2023-02-28 | -6.9% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-10-31 | +6.8% | earnings | Yahoo Finance | Castle Biosciences Inc (CSTL) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance |
| 2022-05-02 | +6.8% | legal | SEC EDGAR | CSTL 8-K: 3.02 (SEC Filing) |
| 2024-11-05 | -6.6% | earnings | Seeking Alpha | Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript |
| 2022-02-28 | +6.3% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-25 | +6.2% | earnings | Seeking Alpha | Castle Biosciences Q4 2025 Earnings Preview |
| 2025-04-14 | +6.2% | earnings | Seeking Alpha | Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern |
| 2025-04-14 | +6.2% | earnings | Seeking Alpha | Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern - Seeking Alpha |
| 2026-03-02 | -5.9% | earnings | Investing.com | Canaccord reiterates Castle Biosciences stock rating on Q4 beat - Investing.com |
| 2023-11-09 | -5.1% | legal | SEC EDGAR | CSTL 8-K: 5.02 (SEC Filing) |
| 2022-06-03 | +5.1% | legal | SEC EDGAR | CSTL 8-K: 8.01 and (SEC Filing) |
| 2022-06-03 | +5.1% | news | Value Research | Castle Biosciences Inc. (CSTL) Share Price Today | Castle Biosciences (CSTL) Live NSE/BSE - Value Research |
| 2021-12-03 | -5.0% | legal | SEC EDGAR | CSTL 8-K: 1.01 and (SEC Filing) |
| 2021-08-09 | -4.9% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-04-16 | +4.3% | news | simplywall.st | When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)? - simplywall.st |
| 2025-05-02 | -3.8% | earnings | Seeking Alpha | Castle Biosciences Q1 2025 Earnings Preview |
| 2026-01-13 | +3.5% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-20 | +3.3% | earnings | simplywall.st | How Investors Are Reacting To Castle Biosciences (CSTL) Upgraded 2025 Revenue Outlook And Test Volume Growth - simplywall.st |
| 2025-12-19 | +3.3% | news | GuruFocus | Castle Biosciences (CSTL) Awards Restricted Stock Units to New E - GuruFocus |
| 2025-09-02 | -3.2% | news | Seeking Alpha | Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential |
| 2025-09-02 | -3.2% | news | Seeking Alpha | Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential (NASDAQ:CSTL) - Seeking Alpha |
| 2026-02-26 | -3.1% | earnings | Seeking Alpha | Castle Biosciences Non-GAAP EPS of -$0.08 beats by $0.18, revenue of $87M beats by $6.69M |
| 2026-02-26 | -3.1% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-26 | -3.1% | earnings | Investing.com | Earnings call transcript: Castle Biosciences Q4 2025 beats expectations, stock rises - Investing.com |
| 2026-02-26 | -3.1% | news | Yahoo Finance | Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results - Yahoo Finance |
| 2026-02-26 | -3.1% | news | Stock Titan | Castle Biosciences (CSTL) swings to 2025 loss as margins compress - Stock Titan |
| 2025-08-03 | +3.1% | earnings | Seeking Alpha | Castle Biosciences Q2 2025 Earnings Preview |
| 2026-04-23 | -2.9% | executive | Stock Titan | Castle Biosciences (NASDAQ: CSTL) CEO sells 4,172 shares via trusts - Stock Titan |
| 2026-04-23 | -2.9% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | CSTL (Castle Biosciences Inc.) reports narrower than expected Q4 2025 loss and slight revenue growth, lifting shares modestly. - Open Stock Signal Network - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-03-06 | -2.7% | earnings | Yahoo Finance | How Castle Biosciences (CSTL) Story Is Shifting With New Revenue Targets And Fair Value - Yahoo Finance |
| 2022-09-01 | -2.7% | analyst | TradingView | CSTL Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-03-31 | +2.7% | legal | Stock Titan | CSTL SEC Filings - Castle Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2026-03-27 | -2.6% | news | PR Newswire | Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 |
| 2026-03-27 | -2.6% | news | Stock Titan | Castle test splits same-stage melanoma patients by 5-year survival odds - Stock Titan |
| 2021-10-19 | +2.5% | legal | SEC EDGAR | CSTL 8-K: 1.01, 7.01, 8.01 (SEC Filing) |
| 2022-11-02 | -2.5% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-01-10 | +2.4% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-02-26 | +2.3% | earnings | Seeking Alpha | Castle Biosciences Q4 2024 Earnings Preview |
| 2026-03-24 | -2.1% | news | Seeking Alpha | Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript |
| 2025-05-21 | -2.1% | news | GuruFocus | Castle Biosciences (CSTL) Target Price Updated by Scotiabank | C - GuruFocus |
| 2021-07-16 | +2.0% | legal | SEC EDGAR | CSTL 8-K: 5.02 (SEC Filing) |
| 2026-03-21 | +1.9% | earnings | Simply Wall St. | Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets |
| 2024-03-27 | +1.8% | legal | SEC EDGAR | CSTL 8-K: 1.01, 5.02 (SEC Filing) |
| 2026-03-30 | +1.8% | news | Seeking Alpha | Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside |
| 2026-03-30 | +1.8% | news | Seeking Alpha | Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside (NASDAQ:CSTL) - Seeking Alpha |
| 2026-03-30 | +1.8% | executive | Stock Titan | Castle Biosciences (CSTL) CEO executes 10b5-1 share sales, exercises options - Stock Titan |
| 2026-03-30 | +1.8% | M&A | Stock Titan | Director at Castle Biosciences (CSTL) acquires 5,329 shares via RSUs - Stock Titan |
| 2026-03-30 | +1.8% | executive | Investing.com | Castle Biosciences CEO Maetzold sells shares worth $106,598 - Investing.com |
| 2021-12-06 | +1.8% | legal | SEC EDGAR | CSTL 8-K: 1.01, 2.01 (SEC Filing) |
| 2026-03-13 | +1.6% | news | Zacks | United Therapeutics Stock Surges 32% in 6 Months: Here's Why |
| 2026-01-23 | +1.6% | news | Yahoo Finance | Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice - Yahoo Finance |
| 2026-01-23 | +1.6% | analyst | DirectorsTalk Interviews | Castle Biosciences, Inc. (CSTL) Stock Analysis: A Healthcare Innovator with Strong Buy Ratings and 9.13% Upside Potential - DirectorsTalk Interviews |
| 2024-01-08 | -1.5% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-09-09 | -1.5% | legal | SEC EDGAR | CSTL 8-K: 8.01 and (SEC Filing) |
| 2026-04-17 | +1.4% | news | DirectorsTalk Interviews | Castle Biosciences, Inc. (CSTL) Stock Analysis: A 97% Upside Potential Beckons Investors - DirectorsTalk Interviews |
| 2026-04-17 | +1.4% | earnings | MarketBeat | Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat |
| 2022-10-12 | -1.4% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Castle Biosciences (CSTL) - Zacks Investment Research |
| 2026-02-09 | -1.4% | news | Yahoo Finance | Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance |
| 2024-02-08 | +1.3% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-06-16 | -1.2% | news | Seeking Alpha | Castle Biosciences partners with SciBase for diagnostic tests |
| 2023-05-03 | +1.2% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-05-09 | -1.1% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-04 | -0.9% | earnings | Simply Wall St. | How Revenue Assumptions Are Rewriting The Story For Castle Biosciences (CSTL) |
| 2026-04-04 | -0.9% | earnings | Yahoo Finance | How Revenue Assumptions Are Rewriting The Story For Castle Biosciences (CSTL) - Yahoo Finance |
| 2022-12-15 | +0.9% | legal | SEC EDGAR | CSTL 8-K: 5.02 (SEC Filing) |
| 2026-03-20 | +0.9% | earnings | Yahoo Finance | Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets - Yahoo Finance |
| 2025-11-12 | -0.8% | earnings | Seeking Alpha | Castle Biosciences, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2022-08-08 | +0.8% | legal | SEC EDGAR | CSTL 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-23 | +0.7% | news | MarketBeat | Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk |
| 2026-03-23 | +0.7% | news | Seeking Alpha | Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study - Slideshow |
| 2026-03-23 | +0.7% | news | Seeking Alpha | Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study - Slideshow (NASDAQ:CSTL) 2026-03-23 - Seeking Alpha |
| 2026-01-11 | +0.7% | news | Yahoo Finance | The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook - Yahoo Finance |
| 2026-01-11 | +0.7% | earnings | GuruFocus | Castle Biosciences (CSTL) Expects 2025 Revenue to Surpass $340 M - GuruFocus |
| 2025-11-06 | -0.6% | news | simplywall.st | Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up - simplywall.st |
| 2026-01-30 | +0.6% | legal | DirectorsTalk Interviews | Castle Biosciences, Inc. (CSTL) Stock Analysis: Uncovering an 18.93% Potential Upside in the Diagnostics Sector - DirectorsTalk Interviews |
| 2026-04-21 | -0.6% | analyst | PR Newswire | Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS |
| 2026-04-21 | -0.6% | news | Stock Titan | New data suggest some early melanomas carry higher relapse risk - Stock Titan |
| 2026-04-10 | -0.5% | legal | PR Newswire | Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year |
| 2026-04-10 | -0.5% | news | Stock Titan | Employees put Castle Biosciences on USA TODAY's workplace list again - Stock Titan |
| 2026-04-10 | -0.5% | earnings | MarketBeat | Castle Biosciences (NASDAQ:CSTL) Shares Down 7% - What's Next? - MarketBeat |
| 2026-03-19 | -0.5% | executive | Investing.com | Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock - Investing.com |
| 2021-09-17 | -0.3% | news | The Motley Fool | Castle Biosciences - CSTL - Stock Price & News - The Motley Fool |
| 2026-03-17 | +0.3% | news | Zacks | CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data |
| 2026-03-17 | +0.3% | legal | Zacks | AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU |
| 2026-04-15 | -0.3% | news | PR Newswire | Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 |
| 2026-04-15 | -0.3% | earnings | Stock Titan | After the close on May 6, Castle Biosciences will break down Q1 - Stock Titan |
| 2025-07-23 | -0.2% | legal | Seeking Alpha | Castle Biosciences, Revolution Medicines get FDA breakthrough statuses |
| 2023-01-20 | +0.0% | legal | SEC EDGAR | CSTL 8-K: 5.02 (SEC Filing) |
| 2026-04-26 | — | news | MSN | What makes Castle Biosciences (CSTL) a good fit for 'trend investing' - MSN |
| 2026-04-24 | — | earnings | MarketBeat | Castle Biosciences (NASDAQ:CSTL) Shares Gap Down on Insider Selling - MarketBeat |